NewAmsterdam Pharma
NewAmsterdam Pharma is a Dutch clinical-stage biopharmaceutical company developing treatments for cardiometabolic disease where existing therapies have proved insufficient or poorly tolerated. Its lead candidate is obicetrapib, an oral, once-daily, low-dose CETP inhibitor intended to lower LDL cholesterol as an adjunct to maximally tolerated statin therapy in high-risk cardiovascular patients. The PREVAIL outcomes trial randomised more than 9,500 patients, and in July 2026 the European Medicines Agency's CHMP issued positive opinions recommending marketing authorisation for obicetrapib as a monotherapy and in fixed-dose combination with ezetimibe. European commercialisation rights are licensed exclusively to the Menarini Group. The company is headquartered in Naarden, the Netherlands, with operations in Miami, and is listed on Nasdaq under the ticker NAMS.
Key facts
| Company Operating Status | Active |
|---|---|
| Full Address | Gooimeer 2-35 1411 DC Naarden The Netherlands |
| Public/Private | Public |
| Stock Symbol | NAMS |
| Ticker Symbol | NAMS |
Open roles at NewAmsterdam Pharma
- Human Resources Project Manager
- Director, Insights and Analytics
- Senior Director, Market Access Pricing & Contracting
- Senior Vice President, Head of Compliance
- Vice President, Commercial Counsel
- Senior Vice President, Head of Global Regulatory Affairs
- Director, Enterprise Data Management & Governance Lead
- Senior Manager, Global Regulatory Affairs
- Director, Global Regulatory Affairs
- Vice President, Go-to-Market and Omnichannel Strategy
- Vice President, Corporate Communications
Browse NewAmsterdam Pharma roles by location: 🌍 Remote
Land a role at NewAmsterdam Pharma
Every live role, the locations NewAmsterdam Pharma hires across, and the company facts — all above.
An email the day NewAmsterdam Pharma posts a role, a cover letter and résumé bullets tailored to each one, and one-click apply.
Get startedEmail & phone for NewAmsterdam Pharma are shown to signed-in members. Sign in →